Clinical trial
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With…
NCT00244829 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00244829 |
|---|---|
| Title | Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia |
| Official title | A Multicenter Pilot Study Evaluating the Safety and Efficacy of Imatinib as Post-Transplant Therapy for High- Risk Philadelphia Chromosome-Positive Leukemias |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | imatinib mesylate, adjuvant therapy |
| Start date | Jan 1, 2004 |
| Completion | Aug 1, 2007 |
| First posted | Oct 27, 2005 |
| Last update posted | Nov 30, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: